Sarepta Therapeutics, Inc.
corporate_fare Company Profile
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 12 items for SRPT at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-09-30, rated 7/10. Across its 12 most recent items scored 7 or higher, the top rating is 9/10, with 5 rated 8 or above. Recent SEC coverage for SRPT spans 8-K, 10-Q, 10-K.
Recent high-impact activity:
- ELEVIDYS Shows Durable Functional Benefit in Older Duchenne Patients, New Data Reveals
- Sarepta Therapeutics Reaches Settlement Agreement with Regenxbio, UPenn, and Catalent
- Sarepta Taps AbbVie Veteran Michael Severino as CEO; Outgoing Chief Ingram to Consult
- FDA Accepts Sarepta's sNDAs for Amondys 45 and Vyondys 53, Sets Feb 2027 PDUFA Date
- Stockholders Approve New Equity Incentive and Employee Stock Purchase Plans
Financial Snapshot
Short Interest & Short Volume
8.02 days to coverFINRA reported short interest of 25,434,681 shares in SRPT as of the September 15, 2026 settlement, a 3.3% increase from the prior period — about 8.0 days to cover at its recent average daily volume. On October 2, 2026, 68.5% of SRPT volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.